EUVIMEDEUVIMED entdecken
Crossref

Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure

Yomara Huertas Gómez, Robert Ferrer Macías, Sebastián I Morales Cancio, Paola Vega González, Laura Rivera Serrano, Marialexandra Addarich Figueroa, Eduardo Colón

Cureus · 29.10.2026

DOI: 10.7759/cureus.118783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 29.10.2026. Verfasst von Yomara Huertas Gómez und 6 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gómez, Y. H., Macías, R. F., Cancio, S. I. M., González, P. V., Serrano, L. R., Figueroa, M. A., & Colón, E. (2026). Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure. Cureus. https://doi.org/10.7759/cureus.118783

Vancouver

Gómez YH, Macías RF, Cancio SIM, González PV, Serrano LR, Figueroa MA, et al. Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure. Cureus. 2026. doi:10.7759/cureus.118783

BibTeX
@article{Gmez2026,
  author = {Gómez, Yomara Huertas and Macías, Robert Ferrer and Cancio, Sebastián I Morales and González, Paola Vega and Serrano, Laura Rivera and Figueroa, Marialexandra Addarich and Colón, Eduardo},
  title = {Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy: Rehospitalization Outcomes in a Predominantly Hispanic Population With Heart Failure},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.118783}
}
Kostenlos starten →